Iovance Biotherapeutics, Inc.’s (NASDAQ:IOVA) 46% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) share price has dived 46% in the last thirty days, prolonging recent pain. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 83% loss during that time.
Since its price has dipped substantially, Iovance Biotherapeutics may be sending very bullish signals at the moment with its price-to-sales (or “P/S”) ratio of 2.8x, since almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 7.7x and even P/S higher than 43x are not unusual. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.
Our free…
